# Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease

> **NCT02689986** · PHASE2 · COMPLETED · sponsor: **Helse Fonna** · enrollment: 43 (actual)

## Conditions studied

- Cold Agglutinin Disease
- Autoimmune Hemolytic Anemia

## Interventions

- **DRUG:** Bendamustine, Rituximab

## Key facts

- **NCT ID:** NCT02689986
- **Lead sponsor:** Helse Fonna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2017-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02689986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02689986, "Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02689986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*